Recombinant Interleukin-2-Expanded Tumor Infiltrating Lymphocytes from Human Renal Cell Cancer Do Not Exhibit Autologous Tumor Cell-Specific Cytotoxicity

1991 ◽  
Vol 47 (1) ◽  
pp. 83-85 ◽  
Author(s):  
T. Nishimura ◽  
Y. Terashima ◽  
T. Hattori ◽  
M. Satoh ◽  
Y. Kondo ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
Tumor Infiltrating Lymphocytes ◽  
Autologous Tumor Cell ◽  
Autologous Tumor ◽  
Specific Cytotoxicity ◽  
Recombinant Interleukin 2 ◽  
Human Renal Cell Cancer ◽  
Infiltrating Lymphocytes

scholarly journals STUDY OF CYTOTOXICITY OF RECOMBINANT INTERLEUKIN-2 (rIL-2) EXPANDED TUMOR INFILTRATING LYMPHOCYTES (TIL) IN RENAL CELL CANCER

1990 ◽  
Vol 81 (6) ◽  
pp. 835-840
Author(s):  
Taiji Nishimura ◽  
Yasunori Terashima ◽  
Tomotaka Hattori ◽  
Mitsuhiro Satoh ◽  
Jun Watanabe ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
Tumor Infiltrating Lymphocytes ◽  
Recombinant Interleukin 2 ◽  
Infiltrating Lymphocytes

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

1988 ◽  
Vol 6 (5) ◽  
pp. 839-853 ◽  
Author(s):  
S L Topalian ◽  
D Solomon ◽  
F P Avis ◽  
A E Chang ◽  
D L Freerksen ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Advanced Cancer ◽  
Adoptive Immunotherapy ◽  
Renal Cell ◽  
Interleukin 2 ◽  
Tumor Infiltrating Lymphocytes ◽  
Lak Cells ◽  
Recombinant Interleukin 2 ◽  
Infiltrating Lymphocytes

Clinical investigations using the adoptive transfer of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) to treat patients with advanced cancer have yielded encouraging results. We have thus sought ways to enhance the effectiveness of adoptive immunotherapy while minimizing its toxic side effects. Murine experiments have identified tumor-infiltrating lymphocytes (TIL) as killer cells more effective than LAK cells and less dependent on adjunctive systemically administered IL-2 to mediate antitumor effects. Accordingly, we performed a pilot protocol to investigate the feasibility and practicality of administering IL-2-expanded TIL to humans with metastatic cancers. Twelve patients, including six with melanoma, four with renal cell carcinoma, one with breast carcinoma, and one with colon carcinoma, were treated with varying doses and combinations of TIL (8.0 X 10(9) to 2.3 X 10(11) cells per patient), IL-2 (10,000 to 100,000 U/kg three times daily to dose-limiting toxicity), and cyclophosphamide (CPM) (up to 50 mg/kg). Two partial responses (PR) to therapy were observed: pulmonary and mediastinal masses regressed in a patient with melanoma, and a lymph node mass regressed in a patient with renal cell carcinoma. One additional patient with breast cancer experienced a partial regression of disease in lymph nodal and cutaneous sites with complete elimination of malignant cells from a pleural effusion, although cutaneous disease recurred at 4 weeks. The toxicities of therapy were similar to those ascribed to IL-2; no toxic effects were directly attributable to TIL infusions. In five of six melanoma patients, TIL demonstrated lytic activity specific for the autologous tumor target in short-term chromium-release assays, distinct from the nonspecific lytic activity characteristic of LAK cells. This study represents an initial attempt to identify and use lymphocyte subsets with enhanced tumoricidal capacity in the adoptive immunotherapy of human malignancies.

Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2

1994 ◽  
Vol 86 (15) ◽  
pp. 1159-1166 ◽  
Author(s):  
S. A. Rosenberg ◽  
J. R. Yannelli ◽  
J. C. Yang ◽  
S. L. Topalian ◽  
D. J. Schwartzentruber ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Interleukin 2 ◽  
Tumor Infiltrating Lymphocytes ◽  
Autologous Tumor ◽  
Infiltrating Lymphocytes

The Effects of Interleukin-6 on Tumor-Infiltrating Lymphocytes Derived from Human Renal Cell Cancer

1991 ◽  
Vol 145 (3) ◽  
pp. 663-667 ◽  
Author(s):  
Tchun Y. Lee ◽  
Alec S. Koo ◽  
Christian Peyret ◽  
Tomoyuki Shimabukuro ◽  
Jean B. Dekernion ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Interleukin 6 ◽  
Renal Cell ◽  
Cell Cancer ◽  
Tumor Infiltrating Lymphocytes ◽  
Human Renal Cell Cancer ◽  
Infiltrating Lymphocytes

The synergistic effects of interleukin 2 and interleukin 7 on the proliferation and autologous tumor cell lysis of tumor-associated lymphocytes

Biotherapy ◽  
1993 ◽  
Vol 6 (3) ◽  
pp. 167-174 ◽  
Author(s):  
Mamoru Tsukuda ◽  
Izumi Mochimatsu ◽  
Miki Sakumoto ◽  
Yasukazu Mikami ◽  
Seiichiro Yuyama ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Synergistic Effects ◽  
Interleukin 2 ◽  
Cell Lysis ◽  
Autologous Tumor Cell ◽  
Autologous Tumor ◽  
Interleukin 7 ◽  
Tumor Cell Lysis
Sign in / Sign up

Export Citation Format

Share Document